KCM
MRKR icon

Kennedy Capital Management’s Marker Therapeutics MRKR Stock Holding History

Kennedy Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-59,012
Closed -$561K – 622
2021
Q4 		$561K Sell
59,012
-2,145
-4% -$28.5K 0.01% 554
2021
Q3 		$1.03M Buy
61,157
+1,023
+2% +$21K 0.02% 524
2021
Q2 		$1.68M Sell
60,134
-120,818
-67% -$3.18M 0.04% 492
2021
Q1 		$4.05M Buy
+180,952
New +$4.14M 0.08% 411

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Kennedy Capital Management's MRKR Position: Q1 2022 in Review

Kennedy Capital Management sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 59,012 shares — an estimated $561K sold.

Kennedy Capital Management first reported a position in MRKR in Q1 2021 and held it in 4 quarters. The position peaked at $4.05M in Q1 2021. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

  • Kennedy Capital Management reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 59,012 Marker Therapeutics shares in Q1 2022, an estimated $561K.
  • Kennedy Capital Management first reported a position in Marker Therapeutics in Q1 2021 and held it in 4 quarters.
  • Kennedy Capital Management's Marker Therapeutics position peaked at $4.05M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Kennedy Capital Management's 13F filing for Q1 2022, filed 16 May 2022.